Invitrogen Shares Plummet 12 Percent on Weak Q3 Results | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Invitrogen were down 11.81 percent, or $7.80, at $58.24 in mid-afternoon trading after the company posted lackluster earnings today.
As GenomeWeb News reported, Invitrogen today said third-quarter revenues increased 7 percent while last year’s profit turned to a loss.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.